Mª Dolores Delgado Villar (IP)

  • IBBTEC. C/ Albert Einstein 22 (PCTCAN); 39011 Santander​
  • maria.delgado@unican.es
  • 942 201998
  • Transcriptional Control of Cancer and Cells and Stem Cells
  • Principal Investigator
  • Cancer
  • Department of Cell & Molecular Signalling

M. Dolores Delgado is Full Professor of Biochemistry and Molecular Biology at the University of Cantabria and develops her research work at the IBBTEC. She holds a degree in Pharmacy from the Complutense University of Madrid and a PhD from the University of Alcalá (Extraordinary Doctorate Award), and has held several postdoctoral stays in France (INSERM, Paris) and the United Kingdom (Univ. Essex). She has extensive research experience in the field of transcription factors involved in cancer. Her group has helped to clarify the role of the transcriptional regulator CTCF in the hematopoietic differentiation in leukemia cells and in the epigenetic regulation of the BCL6 oncogene in lymphoma. She has published in prestigious international journals most from first quartile in the specialties of molecular biology and oncology, and has supervised eight Doctoral Theses and nine Master’s Theses. Her research has been funded continuously by national competitive projects and is currently co-IP of a project of the National R&D Program from Spanish Government. She is evaluator of scientific projects for the State Research Agency and of predoctoral fellowships and reviewer of scientific journals. She teaches undergraduate and master's degrees at the School of Medicine of the UC. She has been Coordinator of the Master in Molecular Biology and Biomedicine, as well as Vice Dean of the Medical School and Coordinator of the PhD Program in Molecular Biology and Biomedicine of the UC Doctoral School. 

​Transcriptional Control in Cancer Cells and Stem Cells

Research lines

    • Roles of MYC network proteins MNT and MXD on cell proliferation  
    • Functional interactions of MYC with cell cycle regulatory proteins
    • MYC target genes in leukemia/lymphoma 
    • Function of the chromatin regulator CTCF in the hematopoietic differentiation
    • CTCF involvement in hematological malignancies, especially in lymphomas. 
    • CTCF regulation of MYCand BCL6 oncogenes.

Funding 

    • Oncoproteínas MYC Y CTCF en el control transcripcional de la diferenciación hematopoyética y en linfoma. SAF2014-53526R. CoIPs: Javier León y M. Dolores Delgado
    • Función de los reguladores transcripcionales CTCF y CTCF-L (BORIS) en la diferenciación hematopoyética normal y patológica. Instituto de Salud Carlos III. FIS11/00397
    • Terapia epigenética en linfomas de células B. Papel de los reguladores de cromatina de la familia CTCF. Entidad financiadora: Celgene S.L.U.
    • "Red Temática Investigación Cooperativa de Investigación en Cáncer" ISCIII-RETIC RD12/0036/0033. IP: Piero Crespo
    • "Functional interaction of MYC and CTCF in aggressive B-cell lymphoma and hematopoietic precursors" SAF2017-88026-R. CoIPs: M. Dolores Delgado y Javier León


A novel role of MNT as a negative regulator of REL and the NF-κB pathway

Liaño-Pons J, Lafita-Navarro MC, García-Gaipo L, Colomer C, Rodríguez J, von Kriegsheim A, Hurlin PJ, Ourique F, Delgado MD, Bigas A, Espinosa ML, León J.

​Oncogenesis. 2021 Jan 8;10(1):5. doi: 10.1038/s41389-020-00298-4.





View more

The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells

The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells

Lafita-Navarro MC, Liaño-Pons J, Quintanilla A, Varela I, Blanco R, Ourique F, Bretones G, Aresti J, Molina E, Carroll P, Hurlin P, Romero OA, Sanchez-Céspedes M, Eisenman RN, Delgado MD, León J.

J Biol Chem. 2020 Feb 14;295(7):2001-2017. doi: 10.1074/jbc.RA119.010389. Epub 2020 Jan 9.


View more

Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.

Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.

Cortiguera MG, García-Gaipo L, Wagner SD, León J, Batlle-López A, Delgado MD.

Sci Rep. 2019 Nov 11;9(1):16495. doi: 10.1038/s41598-019-52714-4.

View more

MYC Oncogene Contributions to Release of Cell Cycle Brakes

MYC Oncogene Contributions to Release of Cell Cycle Brakes

García-Gutiérrez L, Delgado MD, León J.

GENES (Basel). 2019 Mar 22;10(3). pii: E244. doi: 10.3390/genes10030244. 

View more

The epigenetic regulator CTCF modulates BCL6 in lymphoma.

Batlle-López A, Cortiguera MG, Delgado MD. ONCOSCIENCE 2015. 2 (10): 783-784 (Editorial).

​[pubmed]

View more

Myc and cell cycle control.

Bretones G, Delgado MD, León J.Biochim Biophys Acta. 2014 Apr 1. pii: S1874-9399(14)00073-X. doi: 10.1016/j.bbagrm.2014.03.013.

J.Biochim Biophys Acta. 2014Apr 1. pii: S1874-9399(14)00073-X. doi: 10.1016/j.bbagrm.2014.03.013.

View more

MYC as therapeutical target in leukemia and lymphoma.

Cortiguera MG, Batlle-López A, Albajar M, Delgado MD, León J. Blood and Lymphatic Cancer: Targets and Therapy 2015:5 75–91.

​[pubmed]

View more

Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus.

Batlle-López A, Cortiguera MG, Rosa-Garrido M, Blanco R, Del Cerro E, Torrano V, Wagner SD, Delgado MD. Oncogene. 2015 Jan 8;34(2):246-56. doi: 10.1038/onc.2013.535.

[PubMed]

View more

MYC oncogene in myeloid neoplasias.

Delgado, M.D., Albajar, M., Gomez-Casares, M.T., Batlle, A., and León, J. Clin Trans Oncol, 15: 87-94 (2013) .PMID: 22911553.

[pubmed]

View more

The male germ cell gene regulator CTCFL is functionally different from CTCFand binds CTCF-like consensus sites in a nucleosome composition-dependent manner.

Sleutels F, Soochit W, Bartkuhn M, Heath H, Dienstbach S, Bergmaier P, FrankeV, Rosa-Garrido M, van de Nobelen S, Caesar L, van der Reijden M, Bryne JC, vanIjcken W, Grootegoed JA, Delgado MD, Lenhard B, EPIGENETICS & CHROMATIN 2012 Jun 18;5(1):8.

​[pubmed]


View more

A cell cycle role for the epigenetic factor CTCF-L/BORIS.

Rosa-Garrido M, Ceballos L, Alonso-Lecue P, Abraira C, Delgado MD, Gandarillas A. PLoS One.2012;7(6):e39371.

​[pubmed]

View more

MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through down-regulation of p27KIP1 .

Gómez-Casares, M.T. García-Alegria, E., López-Jorge, C.E., Ferrándiz, N., Blanco, R., Alvarez, S., Vaqué, J.P., , Bretones, G., Caraballo, J.M., Sanchez-Bailón, P., Delgado, M.D., Martin-Perez, J., Cigudosa, J.C., and León, J. Oncogene 32:2239- 2246 (2012

[pubmed]

View more

MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.

Albajar, M., Gómez-Casares, M.T., Llorca, J., Mauleon, J., Vaqué, J.P., Acosta, J.C., Bermúdez, A., Donato, N., Delgado, M.D. and León, J. Mol Cancer Res 9: 564-576 (2011).

​[pubmed]

View more

Myc roles in hematopoiesis and leukemia.

Delgado, M.D and León, J. Genes &Cancer (2010) 1: 605–616. Review

​[pubmed]

View more

p21Cip1 confers resistance to imatinib in human chronic myeloid leukemia cells.

Ferrandiz, N, Caraballo, J. M., Albajar, M, Gomez-Casares, M.T., López-Jorge, C.E., Blanco, R., Delgado, M.D. and Leon, J. Cancer Lett 292: 133-139 (2010).

​[pubmed]

View more

CTCF regulates the local epigenetic state of ribosomal DNA repeats.

Van de Nobelen, S., Rosa-Garrido, M., Leers, J., Heath, H., Soochit, W., Joosen, L., Jonkers, I., Demmers, J., Van der Reijden, M., Torrano, V., Grosveld, F., Delgado, M.D., Renkawitz, R., ,Galjart, N..and Sleutels, F. EPIGENETICS & CHROMATIN 2010, 3:19

​[pubmed]

View more

Javier León Serrano (IP)

View more

Lorena García Gaipo

View more

Vanessa Junco Ruisánchez

View more